StaphAcute is an experimental medication being tested for the first time in people. It is given through a single intravenous (IV) infusion, which means it is delivered directly into a vein using a fluid solution. In this trial, researchers are looking at how safe the drug is and how well the body handles it. The study first checks safety in healthy volunteers, then evaluates safety again in patients who have a bloodstream infection caused by Staphylococcus aureus while they are also receiving the usual antibiotic treatment. The goal is to learn whether StaphAcute can be given safely and to understand how it moves through the body.

Methicillin‑susceptible Staphylococcus aureus bacteremia – It is a bloodstream infection caused by Staphylococcus aureus that can be treated with methicillin‑type antibiotics. The bacteria enter the blood, often from a skin wound, catheter, or after surgery, and cause fever, chills, and feeling unwell. As the infection progresses, the bacteria multiply and may travel to other parts of the body such as joints, heart valves, or lungs. Blood cultures remain positive while the bacteria are present, indicating ongoing infection. Over several days the condition can become more widespread if the bacteria are not cleared.

Methicillin‑resistant Staphylococcus aureus bacteremia – It is a bloodstream infection caused by Staphylococcus aureus that does not respond to methicillin‑type antibiotics. The bacteria reach the blood through similar routes, including skin lesions, intravenous lines, or surgical sites, producing fever and systemic symptoms. As the infection advances, the resistant bacteria can spread to organs such as the heart, bones, or lungs. Persistent positive blood cultures show that the bacteria are still present in the bloodstream. The infection may become more extensive over days if the bacteria are not eliminated.